Duravyu (vorolanib intravitreal insert)

Diagnosis and retreatment decisions rely on retinal imaging, principally OCT (CPT 92134), with fluorescein angiography when indicated. In a US Medicare analysis covering 2008 to 2015, reimbursement for OCT imaging used to guide anti-VEGF therapy for neovascular AMD totaled an estimated $0.8 billion, while OCT-guided personalized dosing was estimated to have saved Medicare $10.3 billion in anti-VEGF drug and injection costs, for a net government saving of $9.0 billion. The estimated annual beneficiary copayment for OCT imaging was $6, compared with $242 for aflibercept on a personalized injection schedule. No current Medicare fee schedule amount for OCT or fluorescein angiography was retrieved from a primary CMS source.